AU2013274619B2 - Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide - Google Patents

Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide Download PDF

Info

Publication number
AU2013274619B2
AU2013274619B2 AU2013274619A AU2013274619A AU2013274619B2 AU 2013274619 B2 AU2013274619 B2 AU 2013274619B2 AU 2013274619 A AU2013274619 A AU 2013274619A AU 2013274619 A AU2013274619 A AU 2013274619A AU 2013274619 B2 AU2013274619 B2 AU 2013274619B2
Authority
AU
Australia
Prior art keywords
compound
pyridin
compounds
phenyl
quinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013274619A
Other languages
English (en)
Other versions
AU2013274619A1 (en
Inventor
Jayakumar S. Warrier
Navnath Dnyanoba Yadav
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2013274619A1 publication Critical patent/AU2013274619A1/en
Application granted granted Critical
Publication of AU2013274619B2 publication Critical patent/AU2013274619B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2013274619A 2012-06-11 2013-06-10 Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide Active AU2013274619B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261657913P 2012-06-11 2012-06-11
US61/657,913 2012-06-11
PCT/US2013/044882 WO2013188254A1 (en) 2012-06-11 2013-06-10 Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide

Publications (2)

Publication Number Publication Date
AU2013274619A1 AU2013274619A1 (en) 2015-01-29
AU2013274619B2 true AU2013274619B2 (en) 2017-09-28

Family

ID=48670111

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013274619A Active AU2013274619B2 (en) 2012-06-11 2013-06-10 Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide

Country Status (34)

Country Link
US (1) US9238666B2 (OSRAM)
EP (1) EP2858987B1 (OSRAM)
JP (1) JP6234450B2 (OSRAM)
KR (1) KR102092984B1 (OSRAM)
CN (1) CN104350048B (OSRAM)
AR (1) AR091402A1 (OSRAM)
AU (1) AU2013274619B2 (OSRAM)
BR (1) BR112014030629B1 (OSRAM)
CA (1) CA2876359C (OSRAM)
CL (1) CL2014003361A1 (OSRAM)
CO (1) CO7160032A2 (OSRAM)
CY (1) CY1120432T1 (OSRAM)
DK (1) DK2858987T3 (OSRAM)
EA (1) EA024692B1 (OSRAM)
ES (1) ES2675314T3 (OSRAM)
HR (1) HRP20180815T8 (OSRAM)
HU (1) HUE039210T2 (OSRAM)
IL (1) IL236074A (OSRAM)
LT (1) LT2858987T (OSRAM)
MX (1) MX356699B (OSRAM)
MY (1) MY169219A (OSRAM)
NZ (1) NZ703632A (OSRAM)
PE (1) PE20150228A1 (OSRAM)
PH (1) PH12014502747B1 (OSRAM)
PL (1) PL2858987T3 (OSRAM)
PT (1) PT2858987T (OSRAM)
RS (1) RS57376B1 (OSRAM)
SG (1) SG11201408076WA (OSRAM)
SI (1) SI2858987T1 (OSRAM)
SM (1) SMT201800369T1 (OSRAM)
TN (1) TN2014000499A1 (OSRAM)
TW (1) TWI571470B (OSRAM)
WO (1) WO2013188254A1 (OSRAM)
ZA (1) ZA201500161B (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2014143607A1 (en) * 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Pyrrolopyridazines as potassium ion channel inhibitors
EP2970294B1 (en) * 2013-03-11 2016-12-28 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
JP7110094B2 (ja) * 2015-11-19 2022-08-01 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド 医薬化合物のアミンプロドラッグ

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011028741A1 (en) * 2009-09-03 2011-03-10 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
GB9514380D0 (en) * 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PT1094816E (pt) 1998-07-06 2009-03-10 Bristol Myers Squibb Co Sulfonamidas bifenílicas duplamente antagonistas receptores de angiotensina e endotelina
ES2215474B1 (es) 2002-12-24 2005-12-16 J. URIACH & CIA S.A. Nuevos derivados de fosforamida.
AR049847A1 (es) 2004-07-29 2006-09-06 Merck & Co Inc Inhibidores de los canales de potasio
KR20070092297A (ko) * 2004-12-21 2007-09-12 데브젠 엔브이 Ｋｖ4 이온 채널 활성을 갖는 화합물
US8993552B2 (en) 2009-09-04 2015-03-31 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
WO2011163594A2 (en) * 2010-06-24 2011-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
WO2014143609A1 (en) * 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US9242966B2 (en) * 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011028741A1 (en) * 2009-09-03 2011-03-10 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors

Also Published As

Publication number Publication date
WO2013188254A1 (en) 2013-12-19
AU2013274619A1 (en) 2015-01-29
PH12014502747A1 (en) 2015-02-02
BR112014030629B1 (pt) 2021-12-21
AR091402A1 (es) 2015-02-04
SG11201408076WA (en) 2015-01-29
IL236074A (en) 2016-08-31
CO7160032A2 (es) 2015-01-15
PT2858987T (pt) 2018-07-04
TW201402592A (zh) 2014-01-16
HRP20180815T1 (hr) 2018-06-29
CY1120432T1 (el) 2019-07-10
IL236074A0 (en) 2015-02-01
PH12014502747B1 (en) 2015-02-02
RS57376B1 (sr) 2018-08-31
MX2014014525A (es) 2015-02-24
HK1203928A1 (en) 2015-11-06
CA2876359A1 (en) 2013-12-19
PL2858987T3 (pl) 2018-08-31
JP2015521598A (ja) 2015-07-30
KR20150023667A (ko) 2015-03-05
CN104350048A (zh) 2015-02-11
DK2858987T3 (en) 2018-07-30
SMT201800369T1 (it) 2018-09-13
CA2876359C (en) 2020-01-21
SI2858987T1 (en) 2018-06-29
TN2014000499A1 (en) 2016-03-30
ES2675314T3 (es) 2018-07-10
EP2858987A1 (en) 2015-04-15
PE20150228A1 (es) 2015-02-19
NZ703632A (en) 2016-01-29
HRP20180815T8 (hr) 2019-02-08
JP6234450B2 (ja) 2017-11-22
US9238666B2 (en) 2016-01-19
TWI571470B (zh) 2017-02-21
US20150175641A1 (en) 2015-06-25
MY169219A (en) 2019-03-19
EA201492256A1 (ru) 2016-05-31
HUE039210T2 (hu) 2018-12-28
ZA201500161B (en) 2017-04-26
LT2858987T (lt) 2018-07-10
EA024692B1 (ru) 2016-10-31
KR102092984B1 (ko) 2020-03-24
CL2014003361A1 (es) 2015-05-29
MX356699B (es) 2018-06-11
BR112014030629A2 (pt) 2017-06-27
EP2858987B1 (en) 2018-04-25
CN104350048B (zh) 2016-12-07

Similar Documents

Publication Publication Date Title
EP3124475B1 (en) Quinazolines as potassium ion channel inhibitors
US9242966B2 (en) Phthalazines as potassium ion channel inhibitors
US9458164B2 (en) Pyrrolopyridazines as potassium ion channel inhibitors
DK2858987T3 (en) PHOSPHORAMIC ACID PRODRUGS OF 5- [5-PHENYL-4- (PYRIDIN-2-YLMETHYLAMINO) QUINAZOLIN-2-YL] PYRIDIN-3-SULPHONAMIDE
US9403834B2 (en) Pyrrolotriazines as potassium ion channel inhibitors
HK1203928B (en) Phosphoramidic acid prodrugs of 5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide
JP2008521810A (ja) （２ｓ）−１−［［（７ｒ）−７−（３，４−ジクロロフェニル）−４，７−ジヒドロ−５−メチルピラゾロ［１，５］ピリミジン−６−イル］カルボニル］−２−（４−フルオロフェニル）ピロリジンの新規な結晶形の製造方法、該製造方法において製造される新規な安定な結晶形、および製剤
HK40018229A (en) Quinazolines as potassium ion channel inhibitors
SI23610A (sl) Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ WARRIER, JAYAKUMAR S. AND YADAV, NAVNATH DNYANOBA

FGA Letters patent sealed or granted (standard patent)